Proneness Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.35 M
- Company Age 7 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 6473.98%
- Profit Growth 9832.43%
- Ebitda 778.81%
- Net Worth 20.74%
- Total Assets 708.34%
About Proneness Pharmaceuticals
Proneness Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 07 November 2017 (Seven years and three months 5 days old ). Its registered office is in Lucknow, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.35 M, as per Ministry of Corporate Affairs (MCA) records.
Rajendra Singh and Beena Singh serve as directors at the Company.
Company Details
-
Location
Lucknow, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U74999UP2017PTC098396
-
Company No.
098396
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
07 Nov 2017
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
What products or services does Proneness Pharmaceuticals Private Limited offer?
Proneness Pharmaceuticals Private Limited offers a wide range of products and services, including Common Disease Medicines, Eye Drops.
Who are the key members and board of directors at Proneness Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajendra Singh
|
Director | 07-Nov-2017 | Current |
|
Beena Singh
|
Director | 07-Nov-2017 | Current |
Financial Performance of Proneness Pharmaceuticals.
Proneness Pharmaceuticals Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 6473.98% increase. The company also saw a substantial improvement in profitability, with a 9832.43% increase in profit. The company's net worth Soared by an impressive increase of 20.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Proneness Pharmaceuticals?
In 2021, Proneness Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Proneness Pharmaceuticals?
Unlock and access historical data on people associated with Proneness Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Proneness Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Proneness Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.